Humana upgraded to outperform at Evercore on growth prospects
Evercore ISI upgrades Humana to outperform on Medicare growth and 4-star ratings upside potential. Read more here.
EVERCORE INC A (EVR) is drawing unusual attention today. Our newswire has captured 7 stories on EVR across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100).
Evercore Inc. A (EVR) fell 8.81% to $310.50 in early trading on Tuesday as investors reacted to its second-quarter earnings report. The stock opened with a 4.6% gap down from the previous close and continued to decline throughout the session. The move followed the firm's non-GAAP earnings per share of $2.91, which fell short of the $3.03 consensus estimate, and mixed revenue performance.
Evercore reported second-quarter 2026 results with non-GAAP earnings per share of $2.91, missing estimates by $0.12. While revenue of $999.5 million exceeded expectations by $14.55 million and rose 19% year-over-year, the earnings shortfall weighed on the stock. The firm also announced a quarterly dividend of $0.89 per share. A Form 8-K filed by the company disclosed the results of operations and financial condition, along with related financial statements. The earnings report came after a preview that had highlighted a consensus EPS of $3.03 and revenue of $984.95 million.
Retail traders and investors have shown little activity in the past 24 hours, with no social media chatter reported. The stock's decline follows a recent insider transaction, with the CFO selling $2.7 million worth of shares on June 11. A congressional trade on May 11 saw a member of the House of Representatives purchasing between $15,001 and $50,000 of EVR.
EVR opened at $325.00, reaching a high of $325.15 before falling to a session low of $308.70. The stock closed the session at $311.05, with volume at 0.3 million shares, which is 0.5 times the 3-month daily average. The stock has traded between $265.87 and $388.71 over the past 52 weeks. The company has a market cap of $13.2 billion, a P/E ratio of 19.2, and trailing 12-month revenue growth of 47.2%. The stock has a beta of 1.49, indicating higher volatility than the broader market.
Evercore has no upcoming earnings date to monitor. Investors should watch for changes in coverage and analyst commentary in the coming days as the stock continues to trade near key support levels.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Evercore ISI upgrades Humana to outperform on Medicare growth and 4-star ratings upside potential. Read more here.
Evercore (EVR) Q2 2026 earnings call recap: record revenues, near-record backlog and bullish 2H outlook, plus expense/margin risks and buybacks—read now.
Evercore Inc. (EVR) Q2 2026 Earnings Call July 29, 2026 8:00 AM EDTCompany ParticipantsKaty Haber - Senior MD, Head of Investor Relations & ESGJohn...
Why is Evercore stock sliding today?
Evercore (EVR) Q2 earnings recap: Non-GAAP EPS misses, revenue beats +19% Y/Y, comp ratio improves; shares dip premarket.
Filed: 2026-07-29 AccNo: 0001628280-26-050373 Size: 987 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
EVERCORE INC A (EVR) is drawing unusual attention today. Our newswire has captured 7 stories on EVR across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100). The most recent driver: "Humana upgraded to outperform at Evercore on growth prospects" (Seeking Alpha).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of EVR coverage reads 53/100 over 7 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on EVR: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier EVR move explainers: 2026-07-29